Ionis Pharmaceuticals, Inc. (IONS) Earnings
Ionis Pharmaceuticals, Inc. is expected to report next earnings on November 4, 2026 (in NaN days), with a consensus EPS estimate of $-1.22. IONS has beaten EPS estimates in 9 of its last 11 reported quarters (average surprise +68.6% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 29, 2026 | $-1.08 | $-0.69 | +36.1% | $268M | +41.7% |
| Apr 29, 2026 | $-0.85 | $-0.56 | +34.1% | $246M | +25.8% |
| Feb 25, 2026 | $-1.24 | $-1.41 | -14.3% | $203M | +30.1% |
| Oct 28, 2025 | — | $-0.80 | — | $157M | — |
| Jul 30, 2025 | $0.27 | $0.86 | +218.5% | $452M | +243.1% |
| Apr 30, 2025 | $-1.11 | $-0.75 | +32.4% | $132M | -12.6% |
| Feb 19, 2025 | $-1.09 | $-0.66 | +39.4% | $227M | +72.8% |
| Aug 1, 2024 | $-0.92 | $-0.45 | +51.1% | $225M | +50.1% |
| Feb 21, 2024 | $-0.83 | $-0.06 | +92.8% | $325M | +85.7% |
| Nov 2, 2023 | $-1.04 | $-1.03 | +1.0% | $144M | +8.5% |
| May 3, 2023 | $-0.91 | $-0.87 | +4.4% | $131M | -7.1% |
| Feb 22, 2023 | $-1.06 | $-0.37 | +65.1% | $152M | -5.1% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · July 29, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
### Commercial Milestones - Achieved FDA approval of Tringolza for severe hypertriglyceridemia (SHTG), the first and only approved therapy to reduce triglycerides and acute pancreatitis risk in this patient population. The launch is off to an encouraging start, with prescriptions received on day one of approval and both approved doses in distribution channels within one week. - Donzera for hereditary angioedema (HAE) has gained meaningful market share in the U.S. prophylactic HAE market less than one year post-launch, with growing repeat prescribing driven by positive physician and patient feedback on its efficacy, safety, and patient-friendly administration profile. Partner Otsuka is progressing with the EU launch. - Zilgen-Nersen for Alexander disease is on track for a potential late-2026 launch, with an FDA PDUFA date of September 22, 2026. Commercial preparations are complete, including expanded access programs, patient identification strategies, and a dedicated patient services platform. A partnership with Recordati has been established for ex-U.S. development and commercialization. ### Pipeline Progress - Zobudden-Nersen for Angelman syndrome completed Phase III trial enrollment, keeping it on track for data readout in 2027. - Initiated Phase I-II clinical development of ION 337 for Dravet syndrome, expanding Ionis' wholly owned clinical-stage neurology pipeline to 8 programs. ION 337 uses Ionis' proprietary NMA chemistry for enhanced potency and longer dosing intervals. - Bepiravircin for chronic hepatitis B has an October 26, 2026 PDUFA date in the U.S., with additional global filings under review for a 2026 global launch. - The Phase III Horizon study of Pellicarsin for elevated Lp(a) in cardiovascular disease is on track for data readout in H2 2026. - Partnered pipeline progress includes: Biogen advancing Selenersen for spinal muscular atrophy to Phase III, Biogen planning Phase III development of Dirinersen for early Alzheimer's disease based on promising Phase II data, and Ono initiating the Phase III INTREPID study of sapoblursin for polycythemia vera. ### Financial Highlights - Q2 2026 total revenue was $268 million, and H1 2026 total revenue was $514 million, representing 56% YoY growth in Q2 and 69% YoY growth in H1 (excluding a $280 million one-time milestone from Ono in H1 2025). - Ended Q2 2026 with $2.1 billion in cash, cash equivalents, and short-term investments, providing sufficient capital for pipeline and commercial investments.
Guidance
- Full year 2026 total revenue is maintained at $875 to $900 million, with a slightly higher contribution from commercial revenue than R&D revenue. - Product-level guidance for Tringolza ($100 to $110 million) and Donzera ($110 to $120 million) is maintained, with both expected to return to revenue growth in H2 2026. - 2026 total operating expenses are expected to increase in the low-teens percentage range compared to 2025, driven primarily by sales and marketing costs for ongoing and upcoming commercial launches. - 2026 R&D expenses are expected to remain consistent with 2025, as late-stage studies conclude and resources are redeployed to earlier-stage wholly owned pipeline programs. - Non-GAAP operating loss for 2026 is projected between $425 million and $475 million, consistent with 2025 adjusted for the 2025 one-time license fee. - 2026 year-end cash balance is projected to be greater than $1.6 billion. - The company reaffirmed its target of achieving cash flow break-even in 2028.
Segment performance
### Commercial Medicines Segment - Total commercial revenue: $119 million in Q2 2026, $226 million in H1 2026, representing 15% YoY growth in Q2 and 27% YoY growth in H1. - Tringolza: Generated $5 million in product sales in Q2 2026, and $32 million in H1 2026. The Q2 sales decline followed a strategic April 1 WAC price reduction ahead of SHTG indication expansion; revenue growth is expected to resume in H2 2026. Full-year 2026 product sales guidance is set at $100 to $110 million. - Donzera: Drove the majority of commercial revenue growth, with Q2 2026 sales of $26 million (up 63% quarter-over-quarter from Q1 2026) and H1 2026 sales of $42 million. Full-year 2026 product sales guidance is set at $110 to $120 million, with continued growth expected in H2 2026. ### Partnered Pipeline Segment - Total R&D revenue: $149 million in Q2 2026, and $288 million in H1 2026, reflecting continued progress across partnered development programs. Additional milestone revenue is expected in 2026 from advancing programs including Bepiravircin and Pella Carsin. Segment contribution: Commercial revenue accounted for ~44.4% of total Q2 2026 revenue, while R&D revenue from partnerships accounted for ~55.6% of total Q2 2026 revenue.
Risks & headwinds
- The Phase III CardioTransform study of eplontersin for ATTR cardiomyopathy failed to meet its primary endpoint in the overall study population, creating uncertainty around the drug's regulatory and commercial future for this indication. - Early-stage payer coverage for Tringolza in SHTG is primarily limited to medical exception pathways, and full broad payer coverage will not be in place until late 2026 or 2027, which may limit near-term adoption. - Late-stage pipeline catalysts including the H2 2026 Pellicarsin Horizon study readout carry inherent clinical trial risk; a negative outcome for Horizon would create pressure on the company's ability to meet its 2028 cash flow break-even target. - SHTG lacks a dedicated ICD-10 code, which may create minor administrative and reimbursement barriers for prescribing and coverage. - Tringolza has been associated with small increases in liver fat, though management has noted no associated clinical adverse events and the increases return to baseline with long-term treatment.
Analyst Q&A
Q: Early Tringolza adoption in SHTG is driven largely by existing FCS prescribers, correct? What is the typical timeline from prescription to payer coverage? /
A: Existing FCS prescribers are early adopters, but new non-FCS physicians are already prescribing Tringolza for SHTG as well. Strong FCS demand growth in Q2 will help accelerate the broader SHTG launch. At just a few weeks into the launch, detailed processing timelines are not yet available. Most early approvals are via medical exception, as expected, and management expects coverage to improve through H2 2026 and into 2027. Early payer interactions have been encouraging.
Q: Has the Prasazoran competitor data changed Tringolza's outlook? What is the path to cash flow break-even if the Horizon Pella Carsin trial disappoints? /
A: Management reaffirms Tringolza is a best-in-class therapy for SHTG with strong efficacy, acute pancreatitis risk reduction, safety, and first-mover advantage, and maintains its projection of over $3 billion peak U.S. sales. A negative Horizon outcome would not impact 2026 financial guidance but would create pressure on meeting the 2028 cash flow break-even target. However, management emphasizes that 2028 break-even remains a core priority, and the company will take steps to stay on track.
Q: How does early SHTG launch momentum track against management's full-year guidance? Is there a potential regulatory path for eplontersin in the ATTR cardiomyopathy monotherapy subgroup? /
A: Operationally, the SHTG launch is meeting all early expectations: doses were in channel within one week, field training and marketing deployment went smoothly, and payer and patient services are progressing as planned. Management remains confident in the full-year $100 to $110 million Tringolza sales guidance. Ionis and AstraZeneca are still reviewing CardioTransform data ahead of the ESC presentation. AstraZeneca has not finalized its regulatory strategy, and there is no update to report at this time. Data presented at ESC will show nominally significant efficacy in the baseline monotherapy subgroup, and no benefit in the combination subgroup.
Q: What data will be presented for ION 775 at ESC, and what is the strategic goal for the program? /
A: ESC will feature one-year Phase I data for ION 775, including safety, efficacy, triglyceride and biomarker data. The primary goal of ION 775 is to develop a less frequent dosing alternative to Tringolza for SHTG, as a convenience play; Tringolza already has a best-in-class efficacy profile that is difficult to match. ION 775 is on track for potentially twice-yearly or even once-yearly dosing. Phase IIb enrollment is progressing well, and the path to Phase III will be determined after Phase II data is collected.